An investigation on the changes of serum CCK-8, substance P, and 5-HT in patients with post-stroke insomnia

Technol Health Care. 2023;31(6):2355-2361. doi: 10.3233/THC-230506.

Abstract

Background: At present, the pathogenesis of post-stroke insomnia (PSI) is still inconclusive.

Objective: To explore the changes and significance of serum cholecystokinin-8 (CCK-8), substance P (SP), and 5-hydroxytryptamine (5-HT) in patients with PSI.

Methods: Ninety-one patients with stroke were selected as the research subjects, and according to the score of the Athens Insomnia Scale (AIS), they were divided into the insomnia group and the non-insomnia group. The serum levels of CCK-8, SP, and 5-HT in the two groups were compared to explore their relationships with PSI.

Results: Among the 91 patients, 56 were in the insomnia group and 35 were in the non-insomnia group, and the incidence of insomnia was 61.5%. There was no significant difference in the serum levels of CCK-8, SP, and 5-HT between the two groups (P= 0.696, 0.980, and 0.809, respectively). One-way analysis of variance showed that there was no significant correlation between the serum levels of CCK-8, SP, 5-HT, and the AIS score (P= 0.7393, 0.9581, and 0.5952, respectively).

Conclusion: The incidence of PSI was relatively high, but it could not be proved that CCK-8, SP, and 5-HT were involved in the pathogenesis of PSI. There might exist other neurotransmitters involved in the pathophysiological process of PSI, which should be further explored.

Keywords: 5-hydroxytryptamine; Stroke; cholecystokinin-8; insomnia; serum substance P.

MeSH terms

  • Cholecystokinin
  • Humans
  • Serotonin
  • Sincalide
  • Sleep Initiation and Maintenance Disorders* / epidemiology
  • Sleep Initiation and Maintenance Disorders* / etiology
  • Stroke* / complications
  • Substance P

Substances

  • Serotonin
  • Substance P
  • Sincalide
  • Cholecystokinin